SMGZY News and Press, Smiths Group Plc ADR From 09/22/23

Smiths Group plc ADR (SMGZY) is expected to report for Q4 2023

2023-06-13 04:15:40 ET Summary Smiths Group has the potential for improvement through product innovation and increased M&A. The company is in a commercially attractive position with low cyclicality, operating in industries with growth potential and a wide customer base. A ...

2023-03-29 05:46:12 ET Summary Smiths Group has undergone changes, including the sale of the Medical business and the appointment of a new CEO. SMGZY's 1H23 results were solid, and the raised guidance reflects management's optimism about the state of the market. There is poten...

2023-03-24 11:08:10 ET Smiths Group PLC (SMGKF) Q2 2023 Earnings Conference Call March 24, 2023, 04:30 ET Company Participants Clare Scherrer - CFO & Director Paul Keel - CEO & Executive Director Conference Call Participants Andrew Wilson - JPMorg...

Summary ICU Medical spent far more time, energy, and resources than expected in 2022 on fixing Smiths Medical, but the heavy lifting seems largely done for most of the businesses. Allowing that current results don't reflect the full impact of the improvements management has made, underl...

Smiths Group plc (SMGKF) Q4 2022 Earnings Conference Call September 23, 2022 03:30 AM ET Company Participants Paul Keel - CEO Clare Scherrer - CFO Conference Call Participants Andrew Wilson - JPMorgan Andre Kukhnin - Credit Suisse Mark Davies Jone...

The following slide deck was published by Smiths Group plc in conjunction with their 2022 Q4 earnings call. For further details see: Smiths Group plc 2022 Q4 - Results - Earnings Call Presentation

ICU Medical has fallen well short of expectations for its first year with Smiths Medical in the fold, as the acquired operations have needed considerable work to address operational issues. Core ICU Medical operations are performing reasonably well, with mid-single-digit growth in the...

ICU Medical starts off 2022 with the considerable task of integrating Smiths Medical, a $2.35B deal that significantly expands ICUI's infusion business and adds complementary assets in other departments. In addition to leveraging even more scale, the Smiths deal gives ICU a more compe...

ICU Medical Completes the Acquisition of Smiths Medical from Smiths Group plc The addition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products to the ICU Medical portfolio creates a leading infusion therapy company with a more robu...